#### **Disclaimer**

#### Forward-looking statements

Certain statements contained in this presentation may constitute forward-looking information and statements. All statements in this presentation, other than statements of historical fact, that address events or developments concerning SNDL Inc. ("SNDL" or the "Company") that SNDL expects to occur are "forward-looking information and statements". Forward-looking information and statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "continue", "estimate", "expect", "may", "will", "project", "propose", "potential", "targeting", "intend", "could", "might", "should", "believe", "budgeted", "scheduled" and "forecasts", and similar expressions and variations (including negative variations).

In particular, but without limiting the foregoing, this presentation contains forward-looking information and statements pertaining to the following: SNDL's ability to estigibly the capital triough such transactions; our ability to successfully implement our cost and asset optimization initiatives; the continued development and growth of the demand and markets for medical and adult-use cannabis; the competitive conditions of the industry and the expected number of customers using our products; the maintenance of our existing licenses and the ability to obtain additional licenses as required; our ability to establish and market our brands within our targeted markets and compete successfully; our ability to produce and market additional products as regulations permit; the number of flowering rooms and combined production capacity therefrom that we expect to have; our growth strategies, including plans to sell edibles and other forms of cannabis; the liming and the amount of capital expenditures related to the maintenance and any expansion of our facilities; the outcome of medical research by our partners and the acceptance of such findings in the medical committee; the outcome of medical research by our partners and the acceptance of such findings in the medical amount; our ability to attract and retain key employees; our ability to manage growth in our business; our ability to identify, successfully execute, manage and realize a return on strategic partnerships, joint ventures, strategic alliances, debt and equity investments as well as the costs and benefits associated with such initiatives, including the expected return on any investments; and the volatility in the price of our common shares. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this presentation. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncert

#### Non-IFRS Measures

Certain financial measures in this presentation, including system-wide retail sales, adjusted Operating Income, adjusted EBITDA from continuing operations, free cash flow and gross margin before fair value adjustments, are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures provided by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for measures of performance prepared in accordance with IFRS. For more information in respect of these non-IFRS financial measures, please refer to SNDL's audited consolidated financial statements and the notes thereto for the years ended December 31, 2024 and December 31, 2023, and the accompanying management's discussion and analysis, including the sections thereof entitled "Specified Financial Measures".

#### Important Information Concerning this Presentation

Under no circumstances should the information contained herein be considered an offer to sell or a solicitation of an offer to buy any security of the Company or any other entity in the United States or in any other jurisdiction. The contents of this presentation have not been approved or disapproved by any securities or regulatory authority in Canada, the United States or any other jurisdiction.

In addition, certain information contained in this presentation is based upon information from press releases, independent industry sources and other publications and websites. None of these sources have provided any form of consultation, advice or counsel regarding any aspect of, or is in any way whatsoever associated with, SNDL. Actual outcomes may vary materially from those forecast in such press releases, reports or publications, and the prospect for material variation can be expected to increase as the length of the forecast period increases. While SNDL believes this data and information to be reliable, such data and information is subject to variations and cannot be verified with complete certainty. SNDL has not independently verified any of the data or information from third party sources referred to in this presentation or ascertained the underlying assumptions relied upon by such sources. SNDL cannot and does not provide any assurance as to the accuracy or completeness of such information.

This document is being supplied to you solely for your information and may not be reproduced or forwarded to any other person or published (in whole or in part) for any purpose.

All financial information in this presentation is reported in millions of Canadian dollars unless otherwise indicated.

# SINCI

Corporate Presentation

**SECOND QUARTER 2025** 

NASDAQ: **SNDL** 

CSE: SNDL

### **Q2 2025 Company Highlights**



# CANNABIS REVENUE GROWTH WELL AHEAD OF MARKET

Cannabis business
consistently expanded
revenue YOY in the last
fourteen quarters,
showcasing the benefits of
the Company's vertical
integration strategy



### GROSS MARGIN EXPANSION

All segments expanding gross margin, with Liquor segment reaching new record and Cannabis segments showing strong productivity improvements, including synergies from Indiva acquisition



### FIRST PROFITABLE QUARTER

Q2 marked the first quarter ever with both positive
Operating Income and Net Earnings, underscoring the effectiveness of our strategic improvement agenda

## **Q2 Financial Highlights**

Net Revenue	\$245mm	\$16.6MM Increase YOY	7.3% Increase YOY
Gross Profit	\$67.6mm	\$9.4mm Increase YOY	16.2% Increase YOY
Gross Margin	27.6%	2.1pp Increase YOY	
Adj. Operating Income <sup>1</sup>	\$5.8 <sub>MM</sub>	\$10.4mm Increase YOY	<b>226.3%</b> Increase YOY
Free Cash Flow <sup>2</sup>	\$(7.9)mm	\$(2.3)MM Decrease YOY	(40.7)% Decrease YOY

snot delivered strong results and is well-positioned for success in 2025 and beyond

Financial performance shows clear operational improvements with solid Net Revenue growth, continued Gross Margin expansion and positive Operating Income.

Negative Free Cash Flow driven by growth investments in working capital and CAPEX, and seasonal payments


<sup>&</sup>lt;sup>1</sup>Adjusted operating income (loss) is defined as operating income (loss), less restructuring costs (recovery), goodwill and intangible asset impairments and asset impairments triggered by restructuring activities.

<sup>2</sup>Free cash flow is defined as the total change in cash and cash equivalents less cash used for common share repurchases, dividends (if any), changes to debt instruments, changes to long-term investments, net cash used for acquisitions plus cash provided by dispositions (if any)

#### Second Quarter 2025 Financial Performance


SNDL delivered ~\$6 million in Adjusted Operating Income its first-ever profitable quarter; this milestone was driven by significant gross profit expansion and continued solid net revenue growth above market and key competitors in both Cannabis segments, demonstrating the Company's ability to optimize performance and drive profitability


These results underscore SNDL's positive trajectory toward sustained profitability, while investing in our strategic growth agenda













#### Net Revenue and Gross Profit Contribution by Segments




# Adjusted Operating Income Contribution by Segment and Free Cash Flow drivers



# Q2 negative Free Cash Flow due to seasonal payments, working capital investments and CAPEX to accelerate future growth

#### FCF Breakdown (\$Millions)

	Q1'25	<u>Q2'25</u>
Net Income	(14.7)	2.9
Non-Cash add backs	21.5	16.7
Inventory Change (Inc)/Dec	(6.3)	(1.2)
Other WC change (Inc)/Dec	7.6	(12.4) <sup>(*)</sup>
Capex & Lease payments	(9.2)	(13.8)
Total Free Cash Flow	(1.1)	(7.9)



#### Q2'25 Other WC change include (\*)

- Annual Mngt. Incentive payout
  - Annual Insurance premiums

- \$(8)MM
- \$(3)MM

### **Q2** 2025 **Liquor Retail** Results

- Positive sales performance aided by Easter shift and strong 7.2% Wine & Beyond sales growth
- Private label sales outperforming national brands by 7.8pp in Q2
- Improvement in gross margin was mainly driven by product mix management, pricing and procurement **productivity** initiatives

**Net Revenue** \$141.9<sub>MM</sub> Increase of \$1.4 million 1.0% Increase year-over-year





Adj. Operating Income

\$11.1<sub>MM</sub>

Increase of \$2.6 million

31% Increase year-over-year

- Same store sales growth of 8.2% year-over-year, including uplift from conversions to Value **Buds**
- · Additional net revenue growth from **new store openings**
- Strong Operating Income result driven by business growth, margin expansion, and overhead optimization along with impairment reversals

Net Revenue Increase of \$8.3 million 11% increase year-over-year





Adj. Operating Income

Increase of \$4.2 million

107% increase year-over-year

### Q2 2025 **Cannabis Operations** Results

- Strong net revenue growth as a result of **Indiva acquisition** along with increased International sales (\$3.8 million in Q2), and a continued focus on consumer innovation and *auality*
- Expanded gross margin YOY for the 6th quarter in a row driven by strong productivity programs, operational efficiencies and synergies from Indiva acquisition

Net Revenue \$35.8<sub>MM</sub> Increase of \$10.9 million 43% increase year-over-year



**Gross Margin** 25.8% Up by 13pp from Q2 2024

Adj. Operating Income

\$2.7<sub>MM</sub>

Increase of \$4.6 million

239% increase year-over-year

### **2025 Strategic Priorities**



#### **GROWTH**

Drive sustainable growth in our core segments

- Grow and convert store count
- Grow private label
- Expand digital programs
- Grow market share
- Become a Top 5 LP by the end of 2025



#### **PROFITABILITY**

Consistent Free Cash Flow and Operating Income growth

- Enhance Revenue Streams & Pricing
- Optimize Mix
   Management
- Accelerate Productivity Programs
- Optimize overhead spend



#### **PEOPLE**

Create engagement & alignment through focus on Performance & Talent Development

- Enhance Performance management
- Upgrade talent management and engagement
- Solidify SNDL's 5 core behaviors

# Strategic Priorities

Q2 2025 Highlights



**GROWTH** 

Drive sustainable growth in our core segments

8.2%

Cannabis Retail Same Store Sales Growth

Through quality of execution and Value Buds store conversions, contributing to +0.3pp market share gain

1CM Acquisition

Expansion of Cannabis Retail footprint through acquisition of Cost Cannabis and T Cannabis locations; expected to close in Q3

+2.7%

Liquor Retail Same Store Sales Growth

Supported by Private Label growth of 8.1%, and Wine & Beyond banner growth of 7.2%

+43%

Cannabis Operations
Year-over-year Revenue Growth

Driven by Edibles leadership with Indiva acquisition and International sales

# Strategic Priorities

Q2 2025 Highlights



#### **PROFITABILITY**

Achieving first profitable quarter in company history

+\$6<sub>MM</sub>

Adj. Operating Income

Continued operational improvements and focus on cost management to deliver positive Adjusted Operating Income

~\$3<sub>MM</sub>

**Productivity Savings** 

Segment optimization, including cultivation, procurement efficiencies, and mix management

\$4.7<sub>MM</sub>

Data Licensing Revenue

Combined Revenue from proprietary data licensing program from both Cannabis Retail and Liquor Retail ~\$5<sub>MM</sub>

Overhead Savings

Through prioritization, restructuring program, efficiencies and improved spend management

# Strategic Priorities

Q2 2025 Highlights



#### **PEOPLE**

Create engagement & alignment through focus on performance & talent development



# Strategic Talent Development

Completed the second phase of our annual Strategic Talent Review Program, focusing on 9-box assessments, development planning, and identifying growth opportunities for talent

# Employee Value Proposition

Solidified our action plan based on key opportunities identified in the annual employee engagement survey, and execution of key engagement initiatives is now underway


# Compensation and Talent Reporting


Launched new dashboards to deliver real-time insights on workforce trends and compensation, enabling more informed decision-making, strategic talent discussions, and proactive workforce planning across the business



#### **Key Talent Hires**

Completed the recruitment of several key positions with world class diverse talent, strengthening our talent bench





sndl